STATUTORY RULES.
1963. No. 107.
REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1962.*
I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953-1962.
Dated this thirty-first
day of October , 1963.
DE L’ISLE
Governor-General.
By His Excellency’s Command,
Sgd. H. W. Wade
Minister of State for Health.
Amendments of the National Health (Pharmaceutical Benefits) Regulations.†
Commencement.
1. These Regulations shall come into operation on the first day of November, 1963.
First, Second, Third, Fourth and Fifth Schedules.
2. The First, Second, Third, Fourth and Fifth Schedules to the National Health (Pharmaceutical Benefits) Regulations are repealed and the following Schedules inserted in their stead:—
First Schedule.
Regulation 10.
DRUGS AND MEDICINAL PREPARATIONS IN THE BRITISH PHARMACOPOEIA THAT ARE NOT TO BE SUPPLIED AS, OR USED IN, PHARMACEUTICAL BENEFITS EXCEPT AS SPECIALLY PROVIDED.
Absorbable Gelatin Sponge. Acetazolamide. Acetomenaphthone. Adrenaline Acid Tartrate. Alcohol. Amethocaine Hydrochloride. Amethocaine Injection. Amodiaquine Hydrochloride. Amphetamine. Amphetamine Sulphate. Amylobarbitone Sodium Tablets. Antimony Potassium Tartrate. | Antimony Sodium Tartrate. Antimony Sodium Tartrate Injection. Apomorphine Hydrochloride. Apomorphine Injection. Azovan Blue. Bacillus Calmette-Guerin Vaccine. Bacitracin. Bemegride. Benzhexol Hydrochloride. Bismuth Oxychloride. Bismuth Oxychloride Injection. Bismuth Sodium Tartrate. Busulphan. Butobarbitone. |
* Notified in the Commonwealth Gazette on 31st October, 1963.
† Statutory Rules 1960, No. 17, as amended by Statutory Rules 1960, Nos. 90 and 102; 1961, Nos. 59 and 137; 1962, Nos. 34, 101 and 114; and 1963, Nos. 34 and 69.
9808/63.—Price 1s. 9/18.10.1963.
First Schedule—continued.
Calciferol. Camphor Water. Caraway. Carbachol. Carbimazole. Carbon Dioxide. Carbromal Tablets. Cardamom Fruit. Catgut, sterilized surgical. Cellulose Oxidized. Chlorcyclizine Hydrochloride. Chloroxylenol. Chorionic Gonadotrophin. Chloroquine Phosphate. Chloroquine Sulphate. Chlorothiazide. Chloroxylenol. Chlortetracycline Injection. Cinchocaine Hydrochloride. Cinnamon. Cochineal. Cod Liver Oil. Colchicine. Colchicum Corm. Coriander. Corticotrophin. Cresol. Cresol and Soap Solution. Cyanocobalamin. Cyclobarbitone. Cyclopropane. Dapsone. Dexamphetamine Sulphate. Dextran Injection. Dextran Sulphate. Dextran Sulphate Injection. Dick Control. Dick Test Toxin. Diethylcarbamazine Citrate. Digitalis Leaf. Dimercaprol. Diodone Injection. Diphtheria and Pertussis Vaccine. Dithranol. Emetine and Bismuth Iodide. Emetine Hydrochloride. Ergometrine Maleate. Ether Vinyl. Ethinyloestradiol. Ethisterone. Ethopropazine Hydrochloride. Ethyl Biscoumacetate. Ethyl Chloride. Ethylenediamine Hydrate. Ethyl Oleate. Gallamine Triethiodide. Gallamine Injection. Gentian. Gentian Compound Infusion. Ginger. Halothane. Hamamelis. Helium. | Heparin. Hexamethonium Tartrate. Hexamethonium Tartrate Tablets. Hexamethonium Tartrate Injection. Hexylresorcinol. Histamine Acid Phosphate. Human Blood, whole. Human Red Blood Corpuscles, concentrated. Human Fibrin Foam. Human Fibrinogen. Human Gamma Globulin. Human Gamma Globulin Injection. Human Serum, dried. Human Serum, liquid. Human Plasma, dried. Human Thrombin. Hydrocortisone Acetate Ointment. Hydrocortisone Hydrogen Succinate. Hydrocortisone Ointment. Hydrogen Peroxide Solution, strong. Hydroxychloroquine Sulphate. Hyoscine Eye Ointment. Hyoscyamus. Indigo Carmine. Iodised Oil Injection. Iodoxyl. Iopanoic Acid. Iopanoic Acid Tablets. Ipecacuanha. Ipecacuanha, prepared. Ipecacuanha and Opium Tablets. Isoniazid. Lead Acetate. Lead Monoxide. Lemon Peel, dried. Lemon Peel, fresh. Leptazol. Lignocaine and Adrenaline Injection. Lignocaine Hydrochloride. Lignocaine Hydrochloride Injection. Liothyronine Sodium. Liothyronine Tablets. Lucanthone Hydrochloride. Male Fern. Male Fern Extract. Maleic Acid. Mannitol. Mepacrine Hydrochloride. Mephenesin. Mephenesin Injection. Mercaptofurine. Mercuric Oxide, yellow. Mercury. Mersalyl Acid. Methadone Hydrochloride. Methoin. Methyltestosterone. Methylamphetamine Hydrochloride. Methylthiouracil. Mustine Hydrochloride. Nalorphine Hydrobromide. Naphazoline Hydrochloride. |
First Schedule—continued.
Neostigmine Bromide. Neostigmine Methylsulphate. Nicotinic Acid. Nikethamide. Nikethamide Injection. Nitrous Oxide. Nux Vomica. Oestradiol Benzoate. Opium. Opium, powdered. Orange Peel, dried bitter. Orange Peel, fresh bitter. Ouabain. Oxygen. Oxytetracycline Dihydrate. Paramethadione. Pentamidine Injection. Pentamidine Isethionate. Pethidine Tablets. Phenindamine Tartrate. Phenindione. Pheniodol. Phenolphthalein Tablets. Phenolsulphonphthalein. Phytomenadione. Phytomenadione Capsules. Picrotoxin. Poliomyelitis Vaccine. Potassium Perchlorate. Prednisone Acetate. Primaquine Phosphate. Primidone. Probenecid. Procyclidine Hydrochloride. Procaine and Adrenaline Injection. Progesterone. Proguanil Hydrochloride. Propyliodone. Propyliodone Injection. Propyliodone Oily Injection. Propyl Thirouracil. Pyridostigmine Bromide. Pyrimethamine. | Quillaia. Senna Leaf. Sesame Oil. Soda Lime. Sodium Aminosalicylate Tablets. Sodium Antimonylgluconate. Sodium Antimonylgluconate Injection. Sodium Aurothiomalate. Sodium Radio-iodide (131I) Injection. Sodium Radio-iodide (131I) Solution. Sodium Radiophosphate (32P) Injection. Sodium Radiophosphate (32P) Solution. Sodium Stibogluconate. Sodium Stibogluconate Injection. Solapsone. Solapsone Tablets. Stibophen. Stramonium Dry Extract. Sulphadimidine Sodium. Suramin. Suxamethonium Bromide. Suxamethonium Chloride. Testosterone. Tetrachloroethylene. Tetrachloroethylene Capsules. Thiomersal. Thiopentone Sodium. Thiopentone Injection. Thyroid. Thyroxine Sodium. Tolazoline Hydrochloride. Tolbutamide. Trichloroethylene. Tryparsamide. Tuberculin, old. Tuberculin Purified Protein Derivative. Tubocurarine Chloride. Tubocurarine Injection. Typhoid-Paratyphoid A and B and Cholera Vaccine. Typhoid-Paratyphoid A and B Tetanus Vaccine. Yellow Fever Vaccine. |
Second Schedule.
Regulation 10 (3).
DRUGS AND MEDICINAL PREPARATIONS THAT ARE PHARMACEUTICAL BENEFITS ONLY WHEN PRESCRIBED FOR USE IN A DETERMINED FORM OR IN ALLOWABLE COMPOUNDS.
Pharmaceutical Benefit. | Allowable Compounds (if any). |
Dried Aluminium Hydroxide Gel. B.P. | Prednisolone B.P. with Magnesium Trisilicate B.P. and Dried Aluminium Hydroxide Gel. B.P. |
| Prednisone B.P. with Magnesium Trisilicate B.P. and Dried Aluminium Hydroxide Gel. B.P. |
| Dried Aluminium Hydroxide Gel. B.P. with Magnesium Carbonate B.P. |
Aluminium Hydroxide Gel. B.P. ..... | Aluminium Hydroxide Gel. B.P. with Light Magnesia B.P. |
| Aluminium Hydroxide Gel. B.P. with Magnesium Trisilicate B.P. and Magnesium Hydroxide B.P. |
| Aluminium Hydroxide Gel. B.P. with Kaolin Light B.P. and Pectin |
| Aluminium Hydroxide Gel. B.P. with Magnesium Hydroxide |
| Aluminium Hydroxide Gel. with Magnesium Trisilicate B.P. |
Aluminium Powder .............. | Aluminium Powder with Zinc Oxide B.P. and Liquid Paraffin B.P. |
Aneurine Hydrochloride B.P. ....... | Vitamin A with Aneurine Hydrochloride B.P., Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P. and Vitamin D |
Ascorbic Acid B.P. .............. | Vitamin A with Aneurine Hydrochloride B.P., Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P. and Vitamin D |
Bendrofluazide ................. | — |
Benethamine Penicillin ............ | Benethamine Penicillin with Procaine Penicillin B.P. and Benzylpenicillin Sodium B.P. |
Benzalkonium Chloride ........... | — |
Benzathine Penicillin B.P. .......... | Procaine Penicillin B.P. with Benzylpenicillin B.P. and Benzathine Penicillin B.P. |
Benzylpenicillin B.P. ............. | Fortified Procaine Penicillin Injection B.P. |
| Benzylpenicillin B.P. with Procaine Penicillin B.P. and Streptomycin Sulphate B.P. |
| Procaine Penicillin B.P. with Benzylpenicillin B.P. and Benzathine Penicillin B.P. |
Benzylpenicillin Sodium B.P. ....... | Streptomycin Sulphate B.P. with Benzylpenicillin Sodium B.P. |
| Benethamine Penicillin with Procaine Penicillin B.P. and Benzylpenicillin Sodium B.P. |
Betamethasone Phosphate .......... | — |
Bismuth Subnitrate B.P.C. ......... | Resorcinol B.P. with Bismuth Subnitrate B.P.C, Zinc Oxide B.P., Starch B.P., Cade Oil B.P., Wool Fat B.P., Sodium Metabisulphite, Water, Hard Paraffin B.P. and Yellow Soft Paraffin B.P. |
Butabarbital Sodium ............. | — |
Carbromal B.P. ................. | Pentobarbitone Sodium B.P. with Carbromal B.P. |
Chloramphenicol B.P. ............ | Chloramphenicol B.P. with Borate Buffer and Sterile Distilled Water |
| Chloramphenicol B.P. with Propylene Glycol B.P. |
| Chloramphenicol B.P. with Liquid Paraffin B.P. and White Soft Paraffin B.P. |
| Chloramphenicol B.P. with Polymyxin B. Sulphate B.P. |
Second Schedule—continued.
Pharmaceutical Benefit. | Allowable Compounds (if any). |
Chlorhexidine Diacetate ........... | — |
Chlorpromazine Hydrochloride B.P. ... | — |
Chlortetracycline Calcium .......... | — |
Chlortetracycline Hydrochloride B.P. ... | Chlortetracycline Hydrochloride B.P. with Liquid Paraffin B.P. and White Soft Paraffin B.P. |
Clemizole ..................... | — |
Cortisone Acetate B.P. ............ | — |
Cyclizine Hydrochloride ........... | Cyclizine Hydrochloride with Caffeine B.P. and Ergotamine Tartrate B.P. |
Demethylchlortetracycline Hydrochloride | — |
Dexamethasone Sodium Phosphate .... | — |
Dextrochlorpheniramine Maleate ...... | — |
Dicyclomine Hydrochloride ......... | — |
Dienoestrol B.P. ................. | — |
Diethyl Dithiolisophthalate ......... | — |
Diiodohydroxyquinoline B.P. ........ | — |
Diphtheria Vaccine B.P. ........... | Diphtheria, Tetanus and Pertussis Vaccine B.P. |
| Diphtheria and Tetanus Vaccine B.P. |
Diphtheria and Tetanus Vaccine B.P. ... | — |
Ergotamine Tartrate B.P. ........... | Ergotamine Tartrate B.P. with Caffeine B.P. |
| Ergotamine Tartrate B.P. with Caffeine Citrate B.P.C. and Diphenhydramine Hydrochloride B.P. |
| Ergotamine Tartrate B.P. with Caffeine B.P. and Meclozine Hydrochloride B.P. |
| Ergotamine Tartrate B.P. with Caffeine B.P. and Cyclizine Hydrochloride |
Erythromycin B.P. ............... | — |
Ethotoin ...................... | — |
Ferrous Aminoacetosulphate ........ | — |
Ferrous Succinate ................ | — |
Glucose Indicator ................ | — |
Gramicidin .................... | Gramicidin with Polymyxin B. Sulphate B.P. and Neomycin Sulphate B.P. |
Griseofulvin ................... | — |
Guanethidine Sodium ............. | — |
Haemophilus Influenza Bacterial Serum | — |
Hamamelis Dry Extract ............ | Hamamelis Dry Extract with Zinc Oxide B.P. and Theobroma Oil B.P. |
Hexocyclium Methyl Sulphate ....... | — |
Hydrocortisone B.P. .............. | — |
Hydrocortisone Acetate B.P. ......... | Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P. |
Hydrocortisone Sodium Succinate ..... | — |
Isoprenaline Hydrochloride ......... | — |
Isopropamide Iodide .............. | — |
Levallorphan Tartrate ............. | Levallorphan Tartrate with Pethidine Hydrochloride B.P. |
Lofenalac ..................... | — |
Meclozine Hydrochloride B.P.C. ...... | — |
Mercuric Oxide Eye Ointment B.P. .... | — |
Methazolamide ................. | — |
Methscopolamine Bromide ......... | — |
Methyclothiazide ................ | — |
Methylphenobarbitone B.P.C. ........ | — |
Methylprednisolone .............. | — |
Minafen ...................... | — |
Naphazoline Nitrate B.P. ........... | Antazoline Hydrochloride B.P. with Naphazoline Nitrate B.P. |
Second Schedule—continued.
Pharmaceutical Benefit. | Allowable Compounds (if any). |
Neomycin Sulphate B.P., Eye Drops .... | Polymyxin B. Sulphate B.P. with Bacitracin B.P., Neomycin Sulphate B.P. and Paraffin Base |
| Neomycin Sulphate B.P. with Bacitracin B.P and Polymyxin B. Sulphate B.P |
| Neomycin Sulphate B.P. with Polymyxin B. Sulphate B.P. and Gramicidin |
Nicotinamide B.P. ................ | Vitamin A with Aneurine Hydrochloride B.P. Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P. and Vitamin D |
Oestrone ....................... | — |
Oleandomycin ................... | Tetracycline with Oleandomycin |
Oleoresin Capsicum ............... | Bile Salts with Cascara Sagrada B.P., Phenolphthalein B.P. and Oleoresin Capsicum |
Oxyphencyclimine Hydrochloride ...... | — |
Oxyphenonium Bromide ............ | — |
Oxytetracycline Hydrochloride B.P. ..... | Oxytetracycline Hydrochloride B.P. with Liquid Paraffin B.P. and White Soft Paraffin B.P. |
Papaveretum B.P.C. ............... | Papaveretum B.P.C. with Hyoscine Hydrobromide B.P. |
Papaverine Hydrochloride ........... | — |
Pancreatin B.P. .................. | — |
Pempidine Tartrate ................ | — |
Pentolinium Tartrate B.P. ............ | Pentolinium Tartrate B.P. with Ephedrine B.P. |
Pethidine Hydrochloride B.P. ......... | Pethidine Hydrochloride B.P. with Hyoscine Hydrobromide B.P. |
| Pethidine Hydrochloride B.P. with Levallorphan Tartrate |
Pertussis Vaccine B.P. .............. | Diphtheria, Tetanus and Pertussis Vaccine B.P. |
| Diphtheria and Pertussis Vaccine B.P. |
Phenoxymethylpenicillin B.P. ......... | — |
Phenoxymethylpenicillin (Benzathine Salt) | — |
Phenoxymethylpenicillin Calcium B.P. | — |
Phenoxymethylpenicillin (Hydrabamine Salt) | — |
Phenoxymethylpenicillin Potassium B.P. | — |
Pipenzolate ..................... | — |
Polydimethylsiloxanes ............. | — |
Polymyxin B. Sulphate B.P. .......... | Polymyxin B. Sulphate B.P. with Mucilage of Methylcellulose and Distilled Water B.P. |
| Polymyxin B. Sulphate B.P. with Bacitracin B.P., Neomycin Sulphate B.P. and Paraffin Base |
| Polymyxin B. Sulphate B.P. with Ophthalmic Phosphate Buffer |
| Polymyxin B. Sulphate B.P. with Acetic Acid B.P. and Propylene Glycol B.P. |
| Polymyxin B. Sulphate B.P. with Neomycin Sulphate B.P. and Bacitracin B.P. |
| Polymyxin B. Sulphate B.P. with Tetracycline Hydrochloride |
| Polymyxin B. Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin |
| Polymyxin B. Sulphate B.P. with Chloramphenicol B.P. |
Prednisolone B.P. ................. | Prednisolone B.P. with Magnesium Trisilicate B.P. and Dried Aluminium Hydroxide Gel. B.P. |
| Prednisolone B.P. with Liquid Paraffin B.P. and White Soft Paraffin B.P. |
Second Schedule—continued.
Pharmaceutical Benefit. | Allowable Compounds (if any). |
Prednisolone Disodium Phosphate ...... | — |
Prednisone B.P. .................. | Prednisone B.P. with Magnesium Trisilicate B.P. and Dried Aluminium Hydroxide Gel. B.P. |
Procaine Hydrochloride B.P. ......... | Procaine Hydrochloride B.P. in Normal Saline |
| Tetracycline and Procaine Injection B.P. |
Pyrazinamide ................... | — |
Pyridine Aldoxime Methiodide ........ | — |
Pyrimido-Pyrimidine .............. | — |
Pyrrolidino-Methyl-Tetracycline ....... | — |
Rauwolfia Alkaloids ............... | — |
Roserpine B.P. .................. | — |
Riboflavine B.P. ................. | Vitamin A with Aneurine Hydrochloride B.P., Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P. and Vitamin D |
Sobee ........................ | — |
Sodium Chloride B.P. with Potassium Chloride B.P. and Hydrated Calcium Chloride B.P. in Water for Injection B.P. | Sodium Chloride B.P. with Potassium Chloride B.P., Hydrated Calcium Chloride B.P., Water for Injection B.P. and Dextrose B.P. |
Compound Sodium Lactate Injection B.P. | Compound Sodium Lactate Injection B.P. with Dextrose B.P. |
Sodium Lauryl Sulphate B.P. ......... | Emulsifying Wax B.P. |
Streptomycin Sulphate B.P. .......... | Benzylpenicillin B.P. with Procaine Penicillin B.P. and Streptomycin Sulphate B.P. |
| Benzylpenicillin Sodium B.P. with Streptomycin Sulphate B.P. |
| Streptomycin Sulphate B.P., with Normal Saline |
Sulphadimidine B.P. ............... | Sulphadiazine B.P. with Sulphamerazine B.P. and Sulphadimidine B.P. |
Sulphamerazine B.P. .............. | Sulphadiazine B.P. with Sulphamerazine B.P. and Sulphadimidine B.P. |
| Sulphadiazine B.P. with Sulphamerazine B.P. and Sulphathiazole |
| Sulphadiazine B.P. with Sulphamerazine B.P. and Sulphacetamide |
Sulphacetamide .................. | Sulphadiazine B.P. with Sulphamerazine B.P. and Sulphacetamide |
Sulphathiazole ................... | Sulphadiazine B.P. with Sulphamerazine B.P. and Sulphathiazole |
Tacrine ....................... | Tacrine with Morphine |
Terpineol B.P. ................... | Solution of Chloroxylenol B.P. |
Tetanus Vaccine B.P. .............. | Diphtheria, Tetanus and Pertussis Vaccine B.P. |
Tetracycline Hydrochloride B.P. ....... | Tetracycline Hydrochloride B.P. with Nystatin |
| Tetracycline and Procaine Injection B.P. |
| Tetracycline Hydrochloride B.P. with a buffering agent |
| Tetracycline Hydrochloride B.P. with Liquid Paraffin B.P. and White Soft Paraffin B.P. |
Tetracycline .................... | Tetracycline with Oleandomycin |
Thenalidine .................... | Thenalidine with Calcium Lactate B.P. and Calcium Gluconate B.P. |
Theobroma Prepared B.P.C. .......... | Calcium Gluconate B.P. with Sucrose B.P., Vanillin B.P. and Theobroma Prepared B.P.C. |
Triamcinolone ................... | — |
Trifluoperazine .................. | — |
Tricyclamol Chloride .............. | — |
Tripelennamine Hydrochloride ........ | — |
Troxidone B.P. .................. | — |
Typhoid Para-Typhoid A and B Vaccine B.P. | Typhoid Para-Typhoid A, B and C Vaccine B.P. |
Second Schedule—continued.
Pharmaceutical Benefit. | Allowable compounds (if any). |
Viomycin Pantothenate ........... | Viomycin Sulphate and Viomycin Pantothenate |
Viprynium Embonate ............. | — |
Concentrated Vitamin A Solution B.P. | Concentrated Vitamins A and D Solution B.P. |
Concentrated Vitamin D Solution B.P. | Concentrated Vitamins A and D Solution B.P. |
Vitamin D .................... | Vitamin A with Aneurine Hydrochloride B.P., Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P. and Vitamin D |
Yellow Mercuric Oxide B.P. ........ | Mercuric Oxide Eye Ointment B.P. |
Third Schedule.
Regulation 11.
PHARMACEUTICAL BENEFITS ADDITIONAL TO PHARMACEUTICAL BENEFITS IN THE BRITISH PHARMACOPOEIA.
Acetazolamide Sodium. Acetohexamide. Acetyl-Sulphamethoxypridazine. Aconite Liniment, B.P.C. Acriflavine, B.P. 1948. Acrylic Rosin. Adrenaline Hydrochloride Solution, B.P. 1953. Adrenaline Mucate. Agar, B.P.C. Aloes Pill, B.P. 1948. Aloin, B.P. 1953. Aloxidone. Aluminium Acetate Solution, B.P.C. Aluminium Powder. Amaranth Solution, A.P.F. Amaranth Solution, B.P.C. 1954. Amidopyrine, B.P.C. 1954. Ammonium Acetate, Strong Solution, B.P. 1953. Ammonium Bicarbonate, B.P. 1953. Ammonium Bromide, B.P.C. Amphotericin B. Ampicillin. Androstanolone. Aniseed Water, concentrated, B.P.C. Aniseed Spirit, B.P.C. 1949. Aromatic Ammonia Spirit, B.P. 1953. Aurothioglucose. Balsam of Peru, B.P.C. Beeswax, Yellow, B.P.C. Belladonna Suppository, B.P. 1948. Bendrofluazide. Benzalkonium Chloride. Benzoinated Lard, B.P.C. 1954. Benzol (Commercial). Benzylpenicillin in Oil. Bephenium Hydroxynaphthoate. Betamethasone. Betamethasone Phosphate. Bismuth Glycollylarsanilate. Bismuth Subgallate, B.P.C. Bismuth Subnitrate, B.P.C. Bretylium Tosylate. Brown Snake Antivenene. Buchu Concentrated Infusion, B.P.C. 1954. Butabarbital Sodium. Butyl Aminobenzoate, B.P. 1953. Caffeine Citrate, B.P.C. Cajuput Spirit, B.P. 1948. Calamine Cream, A.P.F. Calcium Aurothiomalate. Calcium Di-Oxytetracycline. Calcium Aminosalicylate, B.P.C. Calcium Phosphate, B.P. 1953. Caluma Concentrated Infusion, B.P. 1948. Calumba Tincture, B.P. 1948. | Camphor Water, concentrated, B.P.C. 1949. Capsicum Ointment, B.P.C. Capsicum Tincture, B.P.C. Caramiphen Hydrochloride. Caraway Oil, B.P.C. Carbinoxamine Maleate. Cardamom Aromatic Tincture, B.P.C. Carmine Solution, A.P.F. Catechu Tincture, B.P.C. Cetyl Alcohol Compound. Charcoal. Chlorambucil. Chloramine, B.P.C. Chlorazanil. Chlorhexidine Diacetate. Chlorobenzol Disulphonamide. Chloroform Water, concentrated, B.P.C. Chlorotrianisene, B.P.C. Chlorpheniramine Maleate. Chlorpropamide. Chlortetracycline Calcium. Chlorthalidone. Spirit of Cinnamon, B.P.C. 1949. Clemizole Hydrochloride. Clemizole Tannate Syrup. Cloves, Concentrated Infusion, B.P.C. 1954. Cloxacillin. Cochineal Tincture, B.P. 1948. Coconut Oil, B.P.C. 1949. Codeine, B.P.C. 1954. Cod Liver Oil Emulsion, B.P. 1953. Colchicine Salicylate. Colistin. Colocynth and Hyoscyamus Pill, B.P.C. Colocynth, B.P.C. Compound Effervescent Powder, B.P. 1953. Creosote, B.P. 1953. Crude Coal Tar. Cudbear Tincture, A.P.F. 1947. Cyclizinc Hydrochloride. Cyclopenthiazide. Cyclophosphamide. Cycloserine. Cycrimine Hydrochloride. Cymogran. Cyproheptadine. Darrow’s Solution. Death Adder Antivenene. Demecarium Bromide. Demethylchlortetracycline Hydrochloride. Desferrioxamine. Deslanoside. Dexamethasone. Dexamethasone Sodium Phosphate. Dextran Iron. Dextrin Iron. |
Third Schedule—continued.
Dextrochlorpheniramine Maleate. Dichlorphenamide. Dicyclomine Hydrochloride. Diethyl Dithiolisophthalate. Diloxanide Furoate. Digitoxin, B.P.C. Dihydroergotamine. Dihydromorphinone Hydrochloride, B.F.C. 1949. Diphenylpyraline Hydrochloride. Diphtheria Toxoid Purified. Dipyridamole. Disodium Diethylstilboestrol Diphosphate. Disodium Dihydrogen Versenate. Dithiazanine Iodide. Dyflos, B.P.C. Ecothiopate Iodide. Ephedrine Sulphate, B.P.C. 1954. Ergot Liquid Extract, B.P.C. 1954. Erythrityltetranitrate, B.P.C. 1949. Erythromycin Glucoheptonate. Erythromycin Propionate. Erythromycin Stearate. Ethionamide. Ethosuximide. Ethotoin. Ethoxzolamide. Ethylidene Dicoumarin. Ethylnoradrenaline. Ferric Hydroxide. Ferrous Aminoacetosulphate. Ferrous Phosphate Compound Syrup, B.P.C. Ferrous Phosphate with Quinine and Strychnine Syrup, B.P.C. Ferrous Succinate. Fludrocortisone Acetate. Fluoxymesterone. Formyl-Tetrahydropteroyl Glutamic Acid. Framycetin Sulphate. Fructose, B.P. 1948. Gall with Opium Ointment, B.P.C. Gelsemium Tincture, B.P.C. Gentian Violet. Glucagon Hydrochloride. Glucose Indicator. Glucose Liquid, B.P. 1953. Glutethimide, B.P.C. Glycerophosphates Compound Syrup, A.P.F. Gramicidin. Griseofulvin. Guanethidine Sodium. Guanethidine Sulphate. Haemophilus Influenza Bacterial Serum. Hamamelis Dry Extract. Heparin Retard. Hexachlorophene, 3% with Entsufon. Hexachlorophene, 3% with Lissapol. Hexachlorophene, 1.5% with Soap Solution. Hexachlorothiazide. Hexocyclium Methyl Sulphate. | Hexoestrol. Honey, Purified, B.P.C. Hydrocalciferol. Hydrocyanic Acid Dilute, B.P.C. 1954. Hydroflumethiazide. Hydroxocobalamin. Hypophosphorous Acid Dilute, B.P.C. Insulin Injection (Specially Purified). Insulin Isophone (N.P.H.). Insulin Isophane (N.P.H.), (Specially Purified). Insulin Special P (Pig). Iodochlorhydroxyquinoline. Iodoform B.P.C. Iodoform Suppository, B.P. 1948. Ipomoea Resin. Iron Aminote. Iron Carbonate Saccharated, B.P.C. Iron Oxide Saccharated. Iron Carbohydrate Complex. Iron Phosphate Compound Syrup, B.P.C. Isoprenaline Hydrochloride. Isopropamide Iodide. Isothipendyl Hydrochloride. Kanamycin Sulphate. Lavender Oil, Spike, B.P.C. Lemon Syrup, neutral, A.P.F. Levallorphan Tartrate. Levorphanol Tartrate, B.P.C. Liothyronine. Lissapol, N 100. Lobelia Ethereal Tincture, B.P.C. Lofenalac. Magenta, B.P.C. Magnesium Bicarbonate Solution, B.P. 1948. Mebhydrolin. Mecamylamine. Mecholyl Chloride. Medroxyprogesterone Acetate. Meclozine Hydrochloride, B.P.C. Mephentermine Sulphate. Mercaptomerin Sodium. Mercuric Chloride, B.P. 1953. Mercurous Chloride Ointment, B.P. 1948. Mercury Compound Ointment, B.P.C. Metaraminol. Metformin. Methazolamide. Methdilazine Hydrochloride. Methenamine Mandelate. Methenolone Acetate. Methenolone Oenanthate. Methicillin. Methotrexate. Methoxamine Hydrochloride, B.P.C. Methscopolamine Bromide. Methyclothiazide. Methyl Androstanolone. Methyl Atropine Nitrate. Methylcellulose, A.P.F. Methylcellulose Mucilage, A.P.F. |
Third Schedule—continued.
Methyldopa. Methyl Prednisolone. Methyl Prednisolone Acetate. Methylandrostenediol. Methylphenobarbitone, B.P.C. Metronidazole. Milk Powder, Synthetic. Minafen. Mitomycin. Myrrh, B.P.C. Myrrh Tincture, B.P.C. Nandrolone Decanoate. Nandrolone Phenylpropionate. Nicoumalone. Niclosamide. Nitrofurantoin. Nitromin. Nitrous Ether Spirit, B.P.C. Norethandrolone. Nux Vomica Extract, Dried, B.P. 1953. Nystatin. Oestradiol Dipropionate. Oestrone. Oleandomycin. Oleoresin Capsicum. Orange Peel Infusion Concentrated, B.P. 1948. Orange Peel Infusion Concentrated, Compound, B.P.C. Orciprenaline. Ox-Bile Extract, B.P. 1948. Oxymel, B.P.C. Oxymel of Squill, B.P.C. Oxymesterone. Oxyphencyclimine Hydrochloride. Oxyphenonium Bromide. Oxytocin Nasal Spray. Pancreatin 4, U.S.N.F. XI. Para-Aminosalicyclic Acid. Paraben Ophthalmic Phosphate Buffer, A.P.F. Paraben Ophthalmic, Vehicle, A.P.F. Paracetamol. Paramethasone Acetate. Papaveretum, B.P.C. Pectin. Pempidine Tartrate. Penicillin Benethamine. Penicillinase. Pentaerythritol Tetranitrate. Penthienate. Pertussis Prophylactic (Haemagglutinin Aluminium Phosphate Adsorbed). Phenazone, B.P.C. Phenazopyradine Hydrochloride. Phenethicillin. Phenformin. Phenoxymethylpenicillin (Benzathine Salt). Phenoxymethylpenicillin (Hydrabamine Salt). Phensuximide. Phenylbutazone. Phenylmercuric Dinaphthylmethane Disulphonate. | Phenytoin. Pholcodine, B.P.C. Pholcodine Citrate Syrup, B.P.C. Phthalylsulphacetamide. Physostigmine Alkaloid. Pipenzolate. Pituitary (Posterior Lobe). Polydimethylsiloxanes. Polythiazide. Potash Sulphurated, B.P.C. Potassium Chlorate, B.P.C. Prednisolone Disodium Phosphate. Prednisolone Sodium Hemisuccinate. Prednisolone Trimethylacetate. Prophenpyridamine Maleate. Prophenpyridamine Para-Aminosalicylate. Propylthiouracil, B.P.C. Protamine Sulphate. Protoveratrines A. Pyrazinamide. Pyridine Aldoxime Methiodide. Pyridoxine Hydrochloride, B.P.C. Pyrrolidino-Methyl-Tetracycline. Quassia Tincture, B.P. 1948. Quillaia Tincture, B.P.C. Quinethazone. Rauwolfia Alkaloids. Red Back Spider Antivenene. Red Syrup. Rheomacrodex, 10% in Dextrose. Ristocetin. Salicylamide. Salicylazosulphapyridine. Senega Concentrated Infusion, B.P.C. Senna Compound Mixture, B.P.C. Senna Fruit Extract. Senna Leaf Concentrated Infusion, B.P.C. Siberian Fir Oil, B.P.C. 1949. Silver Picrate, B.P.C. 1949. Silver Protein Mild, B.P.C. Soap Curd, B.P.C. Soap, Hard. B.P.C. Sobee. Sodium Calcium Edetate. Sodium Carbonate Exsiccated, B.P.C. Sodium Folate. Sodium Lactate. Sodium Nitrite, B.P.C. Sodium Oleate Acid. Sodium Tauroglycocholate. Sorbolene, A.P.F. Spearmint Oil. Spiramycin. Spironolactone. Squill Syrup, B.P.C. Squill Tincture. Squill Vinegar, B.P. 1948. Stearic Acid, B.P.C. Strophanthus Tincture, B.P. 1948. Strychnine, B.P.C. Sulfinpyrazone. Sulphacetamide. Sulphadiazine Sodium. Sulphadimethoxine. |
Third Schedule—continued.
Sulphamethoxydiazine. Sulphamethoxypyridazine. Sulphafurazole. Sulphamethizole. Sulphaphenazole. Sulphathiazole. Sulphapyridine, B.P.C. Sulphuric Acid Dilute, B.P.C. Sulthiame. Surgical Cement. Sustanon. Syntocinon. Tacrine. Taipan Antivenene Talc Purified, B.P.C Testosterone Oenanthate Tetanus Toxoid, Purified Aluminium Phosphate Adsorbed. Tetracycline. Thenalidine Tartrate. Theobromine, B.P.C. Theobroma Prepared, B.P.C. Thiacetazone. Thiambutosine. Thioridazine Hydrochloride. Thyrotrophin. Tiger Snake Antivenene. | Tretamine. Triamcinolone. Triamterene. Triaziquone. Tricyclamol Chloride. Triethanolamine, B.P.C. Triethanolamine Trinitrate. Triethylene Thiophosphoramide. Trifluoperazine. Trimeprazine Tartrate. Trimetaphan Camphorsulphonate. Trinitrophenol, B.P.C. Triprolidine Hydrochloride. Vadrine. Valerian Ammoniated Tincture, B.P.C. Vancomycin Hydrochloride. Vasopressin Tannate in Oil. Velactin. Veriloid. Viomycin Pantothenate. Viomycin Sulphate. Viprynium Embonate. Vitamin A. Vitamin D. Vitamin K. Volatile Bitter Almond Oil, B.P. 1953. Warfarin Sodium. |
Fourth Schedule.
Regulation 12.
ADDITIVES.
Acetone, B.P.C. Alcohol, B.P. Amethocaine Hydrochloride, B.P. Bacitracin, B.P. Carmine Solution, A.P.F. | Cod Liver Oil, B.P. Oil of Caraway, B.P.C. Oil of Citronella, B.P.C. Xylene, B.P.C. 1949. |
_________
Fifth Schedule.
Regulation 14.
PHARMACEUTICAL BENEFITS THE PRESCRIBING OF WHICH IS SUBJECT TO CONDITIONS AND RESTRICTIONS.
Pharmaceutical Benefit. | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act. |
Acetylsalicylic Acid Tablets B.P. | Any disease or condition in a pensioner |
Soluble Acetylsalicylic Acid Tablets B.P. | |
Compound Acetylsalicylic Acid Tablets A.P.F. | |
Compound Acetylsalicylic Acid Tablets B.P.C. | |
Soluble Compound Acetylsalicylic Acid Tablets | |
Acrylic Resin .................... | Ileostomy or colostomy conditions |
Amphotericin B ................... | Systemic fungal infections |
Ampicillin ...................... | Any disease or condition in a pateient receiving treatment in or at an approved hospital |
Androstanolone ................... | Mammary carcinoma |
| With the written authority of the Director-General, long-term steroid therapy |
Aneurine Hydrochloride Tablets B.P. .... | Any disease or condition in a pensioner |
Ascorbic Acid Tablets B.P. ........... | Any disease or condition in a pensioner |
Bemegride Injection B.P. ............ | As an antidote to barbiturate and other hypnotic poisons |
Benzol (Commercial) ............... | Ileostomy or colostomy conditions |
Betamethasone | With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection except Addison’s disease or other forms of adrenocortical hypoplasia |
Busulphan Tablets B.P. .............. | The leukaemias |
Calciferol Tablets B.P. .............. | Any disease or condition in a pensioner |
| With the written authority of the Director-General— |
| Hypoparathyroidism |
| Chronic hypoparathyroid tetany |
| Vitamin D-resistant rickets |
Calciferol Solution B.P. ............. | Any disease or condition in a child under the age of twelve years or in a pensioner |
Calcium Para-Aminosalicylate B.P.C. .... | Tuberculosis |
Calcium Gluconate Effervescent Tablets | Hypoparathyrodism |
Caramiphen Hydrochloride ........... | Parkinsonism |
Chlorambucil .................... | Malignant lymphoma and related conditions |
Chloramine B.P.C, Tablets or Powder | Ileostomy or colostomy conditions |
Chloramphenicol Capsules B.P. ........ | Bacillary dysentery that is resistant both to the Sulphonamides and Streptomycin Sulphate |
| Bacterium coli meningitis, if other forms of treatment are unsuccessful |
| Granuloma inguinale |
| Friedlander bacillus infections |
| Haemophilus influenza infections |
| Lymphogranuloma venereum |
| Salmonella infections |
| Staphylococcal infections |
| Typhoid fever |
| Typhus and other rickettsial diseases |
| Urinary tract infections due to gram negative bacilli that are resistant to the Sulphonamides |
Fifth Schedule—continued.
Pharmaceutical Benefit. | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act. |
Chloramphenicol B.P., Injection ..... | A disease or condition specified in this column in relation to Chloramphenicol Capsules |
Chloramphenicol B.P., Oral Suspension | A disease or condition, specified in this column in relation to Chloramphenicol Capsules, in a child under the age of twelve years |
Chlorotrianisene B.P.C. ........... | Carcinoma of the prostate |
Chlorpheniramine Maleate Oral Linctus | Any disease or condition in a child under the age of twelve years |
Chlorpromazine Hydrochloride B.P. ... | Any disease or condition in a pensioner |
| Any disease or condition in a patient receiving treatment in or at an approved hospital |
| With the written authority of the Director-General, late-stage malignancy |
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine or Thioridazine Hydrochloride |
Chlortetracycline Capsules B.P. ...... | As an alternative to the Penicillins in a person sensitive to the Penicillins |
| Actinomycosis |
| Amoebiasis |
| Bacterial endocarditis (Streptococcus faecalis), acute and sub-acute |
| Bacillary dysentery that is resistant both to the Sulphonamides and Streptomycin Sulphate |
| Bronchiectasis |
| Brucellosis |
| Chancroid |
| Fibrocystic disease of the pancreas |
| Granuloma inguinale |
| Friedlander bacillus infections |
| Leptospirosis |
| Lymphogranuloma venereum |
| Muscoviscidosis |
| Pneumonia that is resistant both to the Penicillins and the Sulphonamides |
| Pre-operative prophylaxis |
| Primary atypical pneumonia |
| Psittacosis |
| Puerperal infections |
| Rat-bite fever (Spirillum minus) |
| Staphylococcal infections |
| Trachoma that is resistant to the Sulphonamides |
| Typhus and other rickettsial diseases |
| Urinary tract infections due to gram negative bacilli that are resistant to the Sulphonamides |
| Whooping cough (Haemophilus pertussis) |
Chlortetracycline Calcium ....... | A disease or condition, specified in this column in relation to Chlortetracycline Capsules, in a child under the age of twelve years |
Chlortetracycline B.P. Granules |
Fifth Schedule—continued.
Pharmaceutical Benefit. | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act. |
Clemizole Tannate Syrup ............ | Any disease or condition in a child under the age of twelve years |
Cloxacillin ...................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Compound Codeine Phosphate Oral Tablet B.P. | Any disease or condition in a pensioner |
Compound Codeine Phosphate Soluble Oral Tablet B.P. | |
Codeine Phosphate B.P. with Acetylsalicylic Acid B.P. Soluble Oral Tablet | |
Codeine Phosphate B.P. with Acetylsalicylic Acid B.P. Oral Tablet | |
Codeine Phosphate B.P. with Pentobarbitone Sodium B.P. and Phenacetin B.P. Oral Tablet | |
Codeine Phosphate B.P. with Acetylsalicylic Acid B.P. and Phenacetin B.P. Oral Tablet | |
Codeine Phosphate B.P. with Acetylsalicylic Acid B.P., Phenacetin B.P. and Caffeine B.P. Oral Tablet | |
Cod Liver Oil, B.P. ............... | Any disease or condition in a child under the age of twelve years or in a pensioner |
Cod Liver Oil Emulsion B.P. 1953 | |
Colistin ........................ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
| With the written authority of the Director-General— |
Corticotrphin Injection B.P. ........... | A disease or condition specified in this column in relation to Cortisone Injection |
Corticotrophin Gelatin Injection B.P. | |
Corticotrophin Zinc Hydroxide Injection B.P. | Hypsarrhythmia |
Salaam convulsions | |
| The treatment of side effects of corticosteroid therapy |
Cortisone Injection B.P. ............. | With the written authority of the Director-General— |
| Anaemia, acquired haemolytic |
| Addison’s disease or other forms of adrenocortical hypoplasia |
| Adrenalectomy, total |
| Adrenogenital syndrome |
| Behcet’s syndrome |
| Cranial arteritis |
| Cushing’s syndrome, including hyperadrenocorticalism |
| Dermatitis, acute exfoliative, associated with drug therapy |
| Dermatomyositis |
| Encephalomyelitis |
| Guillain-Barre syndrome |
| Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis |
| Hansen’s disease |
| Hepatitis, progressive or continuing, proven by biopsy or biochemistry |
| Hodgkin’s disease |
| Idiopathic hypercalcaemia |
| Keratoplasty |
Fifth Schedule—continued.
Pharmaceutical Benefit. | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act. |
Cortisone Injection B.P.—continued. | The leukaemias |
| Lymphosarcoma and follicular lymphoma |
| Metastatic breast carcinoma |
| Nephritis, type II. |
| Nephrosis or nephrotic syndrome |
| Neuro-myelitis optica |
| Optic neuritis following removal of tumor of the brain |
| Panhypopituitarism |
| Pemphigus |
| Periarteritis nodosa |
| Progressive transverse myelitis |
| Pseudohermaphroditism |
| Purpura, Henoch’s |
| Purpura, thrombocytopenic |
| Reticulum cell sarcoma |
| Rheumatic carditis, acute |
| Sarcoidosis |
| Scleroderma |
| Severe reactions of the skin and mucosa following X-ray therapy |
| Splenic neutropenia and agranulocytosis |
| Status asthmaticus |
| Steroid therapy prior to operation in patients under steroid therapy |
| Stevens-Johnson syndrome |
| Still’s disease in a child under the age of sixteen years |
| Sympathetic ophthalmitis |
| Systemic lupus erythematosus |
| Temporal arteritis |
| Tropical and non-tropical sprue and all forms of mal-absorption associated with those diseases |
| Ulcerative colitis proven by sigmoidoscopy or radiological report |
| Uveitis, posterior |
Cortisone Tablets B.P. .............. | With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection |
Cyanocobalamin Injection B.P. (other than 1,000 microgramme strength) | Established megalocytic anaemias |
Cyanocobalamin Injection B.P., 1,000 microgramme strength | Neuroblastoma |
Cymogran ...................... | With the written authority of the Director-General, phenylketonuria |
Cycloserine ..................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Demethylchlortetracycline Hydrochloride | A disease or condition specified in this column in relation to Chlortetracycline Capsules |
Deoxycortone Acetate B.P. .......... | Addisons’s disease Total adrenalectomy |
Deoxycortone Acetate Injection B.P. | |
Deoxycortone Acetate Implant B.P. | |
Desferrioxamine .................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Dexamethasone ................... | With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection except Addison’s disease or other forms of adrenocortical hypoplasia |
Fifth Schedule—continued.
Pharmaceutical Benefit. | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act. |
Dextrochlorpheniramine Maleate Syrup | Any disease or condition in a child under the age of twelve years |
Dicyclomine Hydrochloride, Oral Syrup | Any disease or condition in a child under the age of twelve years |
Dienoestrol B.P., Cream ............. | Any disease or condition in a pensioner |
Dienoestrol Tablets B.P. ............. | Carcinoma of the prostate |
| Mammary carcinoma |
| Any disease or condition in a pensioner |
Diethyl Dithiolisophthalate ........... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Diiodohydroxyquinoline B.P., Vaginal Tablet | Trichomonal and monilial vaginitis |
Diiodohydroxyquinoline B.P., Compound Effervescent Gynaecological Pessary | Trichomonal and monilial vaginitis |
Dihydrostreptomycin Sulphate Injection B.P. | As an alternative to Streptomycin Sulphate in a person who is being treated for a disease or condition specified in this column in relation to Streptomycin Sulphate and who is allergic to Streptomycin Sulphate |
Diloxanide Furoate ................ | Amoebic dysentery |
Diphenhydramine Hydrochloride B.P., Elixir | Any disease or condition in a child under the age of twelve years |
Disodium Diethylstilboestrol Diphosphate | Carcinoma of the prostate |
Ephedrine Hydrochloride with Phenobarbitone, Elixir | Any disease or condition in a child under the age of twelve years |
Erythromycin B.P. ............... | A disease or condition in this column in relation to Chlortetracycline Capsules |
Erythromycin Tablets B.P. ......... | |
Erythromycin Glucoheptonate | |
Erythromycin Propionate .......... | |
Erythromycin B.P., Oral Sachet | A disease or condition specified in this column in relation to Chlortetracycline Capsules in a child under the age of twelve years |
Erythromycin B.P., Oral Suspension | |
Erythromycin Stearate, Oral Suspension | |
Ethinyloestradiol Tablets B.P. ......... | Turner’s syndrome |
| Pre-menopausal castration syndrome |
| Any disease or condition in a pensioner |
Ethionamide ..................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Ethisterone Tablets B.P. ............. | Turner’s syndrome |
| Habitual abortion |
| Any disease or condition in a pensioner |
Ethosuximide, Oral Syrup ............ | Any disease or condition in a child under the age of twelve years |
Ferric Hydroxide Colloidal Solution | Any disease or condition in a child under the age of twelve years |
Ferrous Aminoacetosulphate Syrup | |
Ferrous Gluconate Elixir ........... | |
Ferrous Succinate Syrup ........... | |
Ferrous Sulphate Oral Drops | |
Fludrocortisone Acetate.............. | With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection |
Fluoxymesterone .................. | Mammary carcinoma |
Folic Acid B.P. ................ | Macrocytic anaemic |
Folic Acid Tablets B.P............. | Sprue or the sprue-like syndrome |
Formyl-Tetrahydropteroyl Glutamic Acid | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Fusidic Acid .................. |
Fifth Schedule—continued.
Pharmaceutical Benefit. | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act. |
Griseofulvin ................... | With the written authority of the Director-General— |
| For the treatment of any of the following diseases, the diagnosis of which has been confirmed by pathological report:— |
| Epidermophyton floccosum |
| Microsporum audouni |
| Microsporum canis |
| Microsporum gypseum |
| Trychophyton interdigitale |
| Trichophyton mentagrophytes |
| Trichophyton rubrum |
| Trichophyton schoenleini |
| Trichophyton sulphureum |
| Trichophyton verrucosum |
Haemophilus Influenza Bacterial Serum | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Hexachlorophene, 3% with Entsufon | |
Hexachlorophene, 3% with Lissapol | |
Hexachlorophene, 1.5% with Soap Solution | |
Hydrocalciferol ................. | Parathyroid deficiency |
Hydrocortisone Injection B.P. ........ | With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection |
Hydrocortisone Sodium Succinate B.P. | With the written authority of the Director-General, ulcerative colitis proven by sigmoidoscopy or radiological report |
Hydrocortisone Sodium Succinate Injection B.P. | Acute adrenal failure due to a medical or surgical crisis |
| Stevens-Johnson syndrome |
Hydroxocobalamin Injection, 100 microgramme strength | Established megalocytic anaemia |
Hydroxocobalamin Injection, 1,000 microgramme strength | Sub-acute combined degeneration of the cord |
| Neuroblastoma |
Isionazid Tablets B.P. ............. | Hansen’s disease |
| Tuberculosis |
Kanamycin Sulphate .............. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Levorphanol Tartrate B.P.C. ......... | Obstetrical use |
| Severe intractable pain |
Liothyronine ................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Lissapol Deodorant Detergent (Lissapol N100 with Spearmint Oil and Cetrimide) | Ileostomy or colostomy condition |
Lofenalac ..................... | With the written authority of the Director-General, phenylketonuria |
Malt Extract B.P. ................ | Any disease or condition in a child under the age of twelve years or in a pensioner |
Malt Extract with Cod Liver Oil B.P. | |
Mebhydrolin Suspension ........... | Any disease or condition in a child under the age of twelve years |
Medroxyprogesterone Acetate ....... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Mepyramine Maleate Elixir ......... | Any disease or condition in a child under the age of twelve years |
Mercaptopurine Tablets B.P. ........ | Allergic angiitis |
| Periarteritis |
| Systemic lupus erythematosus |
| The leukaemias |
Fifth Schedule—continued.
Pharmaceutical Benefit. | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act. |
Methdilazine Hydrochloride Syrup .... | Any disease or condition in a child under the age of twelve years |
Methenolone Acetate ............. | Senile osteoporosis proven by radiological report |
| With the written authority of the Director-General, long-term steroid therapy |
Methenolone Oenanthate ........... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Methicillin .................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Methotrexate .................. | The leukaemias and neo-plastic disease |
Methyl Androstanolone ........... | Mammary carcinoma |
| With the written authority of the Director-General, long-term steroid therapy |
Methylandrostenediol ............. | Senile osteoporosis proven by radiography |
| With the written authority of the Director-General, long-term steroid therapy |
Milk Powder, Synthetic ........... | With the written authority of the Director-General, galactosaemia |
Minafen ...................... | With the written authority of the Director-General, phenylketonuria |
Mitomycin .................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Morphine with Tacrine, 30 mg.-15 mg. Oral Tablet | Severe intractable pain |
Mustine Injection B.P. ........... | Malignant lymphoma and related conditions Mammary carcinoma |
Nandrolone Phenylpropionate | With the written authority of the Director-General, long-term steroid therapy |
Nandrolone Decanoate ........... | |
Neomycin Sulphate B.P., in a form other than Eye Drops | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Nicotinamide Tablets B.P. .......... | Any disease or condition in a pensioner |
Nicotinic Acid Tablets B.P. ......... | Any disease or condition in a pensioner |
Nitrofurantoin .................. | Urinary tract infections |
Nitrofurantoin Suspension .......... | Any urinary tract infection in a child under the age of twelve years |
Nitromin ..................... | Malignant lymphoma and related conditions |
Norethandrolone ................ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Novobiocin Calcium B.P. ......... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Novobiocin Sodium B.P. .......... | |
Novobiocin Tablets B.P. .......... | |
Nystatin ...................... | Proven monilia infections |
Orciprenaline .................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Oxymesterone .................. | Senile osteoporosis proven by radiological report |
| With the written authority of the Director-General, long-term steriod therapy |
Oxytetracycline Tablets B.P. | A disease or condition specified in this column in relation to Chlortetracycline Capsules |
Oxytetracycline Injection B.P. | |
Oxytetracycline and Procaine Injection B.P. | |
Calcium Di-Oxytetracycline ........ | A disease or condition, specified in this column in relation to Chlortetracycline Capsules, in a child under the age of twelve years |
Oxytetracycline Paediatric Drops | |
Oxytocin Nasal Spray.............. | Induction of labour |
Pancreatin B.P. ................ | Fibrous disease of the pancreas |
Pancreatin Enzyme 4, U.S.N.F. XI. | Pancreatico-duodenectomy |
Pancrex 5 .................... | Pancreatic steatorrhea |
Para-Aminosalicylic Acid .......... | Tuberculosis |
Paracetamol, Oral Suspension ....... | Any disease or condition in a child under the age of twelve years |
Fifth Schedule—continued.
Pharmaceutical Benefit. | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act. |
Paramethasone Acetate .............. | With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection |
Paraffin Liquid Emulsion B.P. ......... | Any disease or condition in a pensioner |
Pethidine and Levallorphan Tartrate ..... | Obstetrical use |
Phenoxymethylpenicillin B.P., Oral Suspension | Any disease or condition in a child under the age of twelve years |
Phenoxymethylpenicillin (Benzathine Salt), Oral Suspension | |
Phenoxymethylpenicillin Calcium B.P., Oral Suspension | |
Phenoxymethylpenicillin (Hydrabamine Salt), Oral Suspension | |
Phenoxymethylpenicillin Potassium B.P., Oral Suspension | |
Benzylpenicillin B.P., with Procaine Penicillin B.P. and Streptomycin Sulphate B.P. | Endocarditis due to Streptococcus faecalis or Streptococcus viridans |
Phenacetin ...................... | Any disease or condition in a pensioner |
Phenytoin Sodium B.P., Oral Suspension | Any disease or condition in a child under the age of twelve years |
Phytomenadione Injection B.P. ......... | Antidote to anticoagulants |
Piperazine Citrate B.P., Elixir ......... | Any disease or condition in a child under the age of twelve years |
Pituitary Posterior Lobe B.P.C., Insufflation | Diabetes insipidus |
Polydimethylsiloxanes .............. | Ileostomy or colostomy conditions |
Prednisolone Disodium Phosphate ...... | With the written authority of the Director-General, ulcerative colitis proven by sigmoidoscopy or radiological report |
Prednisolone Tablets B.P. ............ | With the written authority of the Director-General— |
| Anaemia, acquired haemolytic |
| Adrenogenital syndrome |
| Behcet’s syndrome |
| Cranial arteritis |
| Cushing’s syndrome, including hyperadrenocorticalism |
| Dermatitis, acute exfoliative, associated with drug therapy |
| Dermatomyositis |
| Encephalomyelitis |
| Guillain—Barre syndrome |
| Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis |
| Hansen’s disease |
| Hepatitis, progressive or continuing, proven by biopsy or biochemistry |
| Hodgkin’s diesease |
| Idiopathic hypercalcaemia |
| Inflammatory conditions of the uveal tract and retina |
| Keratoplasty |
| The leukaemias |
| Lymphosarcoma and follicullar lymphoma |
| Metastatic breast carcinoma |
| Nephritis, type II. |
| Nephrosis or nephrotic syndrome |
| Neuro-myelitis optica |
| Nodular non-suppurative pannicultitis (Christian-Weber disease) |
Fifth Schedule—continued.
Pharmaceutical Benefit. | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act. |
Prednisolone Tablets B.P.—continued. | Optic neuritis following removal of tumour of the brain |
| Panhypopituitarism |
| Pemphigus |
| Periarteritis nodosa |
| Progressive transverse myelitis |
| Pseudohermaphroditism |
| Purpura, Henoch’s |
| Purpura, thrombocytopenic |
| Reticulum cell sarcoma |
| Rheumatic carditis, acute |
| Sarcoidosis |
| Scleroderma |
| Severe reactions of the skin and mucosa following X-ray therapy |
| Splenic neutropena and agranulocytosis |
| Status asthmaticus |
| Steroid therapy prior to operation in patients under steroid therapy |
| Stevens-Johnson syndrome |
| Still’s disease in a child under the age of sixteen years |
| Sympathetic ophthalmitis |
| Systemic lupus erythematosus |
| Temporal arteritis |
| Tropical and non-tropical sprue and all forms of mal-absorption associated with those diseases |
| Ulcerative colitis proven by sigmoidoscopy or radiological report |
| Uveitis, posterior |
Methyl Prednisolone ............... | With the written autority of the Director General, a disease or condition specified in this column in relation to Prednisolone Tablets |
Prednisolone Acetate B.P. ............ | With the written authority of the Director-General a disease or condition specified in this column in relation to Cortisone Injection except Addison’s disease or other forms of adrenocortical hypoplasia |
Prednisolone B.P. with Magnesium Trisilicate B.P. and Dried Aluminium Hydroxide Gel. B.P. | With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection |
Prednisolone Sodium Hemisuccinate | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Prednisone Tablets B.P. ............. | With the written authority of the Director-General— |
| A disease or condition specified in this column in relation to Cortisone Injection except Addison’s disease or other forms of adrenocortical hypoplasia and total adrenalectomy |
| Nodular non-suppurative panniculitis (Christian-Weber disease) |
| Inflammatory conditions of the uveal tract and retina |
Prednisone B.P. with Magnesium Trisilicate B.P. and Dried Aluminium Hydroxide Gel. B.P. | With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection |
Fifth Schedule—continued.
Pharmaceutical Benefit. | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act. |
Progesterone Injection B.P. ........ | Habitual abortion |
Promethazine Hydrochloride B.P., Elixir | Any disease or condition in a child under the age of twelve years |
Prophenpyridamine Maleate, Oral Syrup | Any disease or condition in a child under the age of twelve years |
Protoveratrines A ............... | Hypertensive crisis |
Pyrazinamide ................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Pyridine Aldoxime Methiodide ...... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Pyridoxine Hydrochloride, Oral Tablet, B.P.C. | Peripheral neuritis due to isoniazid therapy |
Radiation sickness | |
Pyridostigmine Injection B.P. ....... | Myasthenia gravis |
Pyridostigmine Tablets B.P. ........ | Myasthenia gravis |
Quinethazone ................ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Rheomacrodex, 10% in Dextrose | |
Riboflavine Tablets B.P. .......... | Any disease or condition in a pensioner |
Ristocetin .................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Senna Fruit Extract .............. | Any disease or condition in a pensioner |
Sobee ....................... | With the written authority of the Director-General, galactosaemia |
Sodium Aminosalicylate B.P. | Tuberculosis |
Sodium Aminosalicylate Tablets B.P. | |
Sodium Folate ................. | Macrocytic anaemia |
| Sprue or the sprue-like syndrome |
Spiramycin ................... | Staphylococcal infections that are resistant both to the Tetracyclines and to the Penicillins |
Spironolactone ................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Stilboestrol B.P. ............... | Carcinoma of the prostate |
Stilboestrol Tablets B.P. .......... | Mammary carcinoma |
| Any disease or condition in a pensioner |
Streptomycin Sulphate B.P. ........ | Bacillary dysentery that is resistant to the Sulphonamides |
| Brucellosis |
| Chancroid |
| Endocarditis due to Streptococcus faecalis or Streptococcus viridans |
| Friedlander bacillus infections |
| Haemophilus influenzae infections Plague |
| Pseudomonas pyocyaneus infections |
| Rat-bite fever (Streptobacillus moniliformis) |
| Salmonella infections |
| Surgical conditions of the bowel (pre-operative and post-operative) |
| Surgical conditions of the thoracic organs |
| Tuberculosis |
| Tularaemia |
| Urinary tract infections that are resistant to the Sulphonamides |
Streptomycin Sulphate Injection B.P. .. | A disease or condition specified in this column in relation to Streptomycin Sulphate |
Streptomycin Sulphate B.P. with Benzylpenicillin Sodium, B.P. | Endocarditis due to Streptococcus faccalis or Streptococcus viridans |
Sulphadimethoxine Suspension | Any disease or condition in a child under the age of twelve years |
Sulphadimidine Oral Suspension | |
Sulphaphenazole Syrup ......... | |
Sulphasalazine ................. | Ulcerative colitis |
Fifth Schedule—continued.
Pharmaceutical Benefit. | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may he prescribed) for supply under Part VII. of the Act. |
Sulthiame ....................... | For use where other anti-convulsants have failed |
Surgical cement ................... | Ileostomy or colostomy conditions |
Sustanon ....................... | Castration syndrome Mammary carcinoma |
Testosterone Implants B.P. ........... | |
Testosterone Oenanthate ............ | |
Testosterone Propionate Injection B.P. | Castration syndrome |
Testosterone Propionate B.P. | Kline felter Reifenstein Albright syndrome |
Methyltestosterone Tablets B.P. | Mammary carcinoma |
Tetracycline with a buffering agent and Amphotericin B | A disease or condition specified in this column in relation to Tetracycline with Nystatin in a child under the age of twelve years |
Tetracycline Capsules B.P. ........... | A disease or condition specified in this column in relation to Chlortetracycline Capsules |
Tetracycline Tablets B.P.............. | |
Tetracycline and Procaine Injections B.P. | |
Tetracycline Hydrochloride B.P., with a buffering agent—Capsules | |
Tetracycline Injection B.P. ........... | |
Tetracycline with Oleandomycin Capsules | |
Pyrrolidino-Methyl-Tetracycline | |
Tetracycline with a buffering agent—Oral Suspension | A disease or condition, specified in this column in relation to Chloretracycline Capsules, in a child under the age of twelve years |
Tetracycline with a buffering agent—Paediatric Drops | |
Tetracycline with Oleandomycin—Oral Suspension | |
Tetracycline with Oleandomycin—Paediatric Drops | |
Tetracycline with Nystatin............. | Broad spectrum antibiotic therapy of premature infants, of patients under steroid therapy or of cases complicated by intestinal moniliasis |
| A second or repeated course of broad spectrum antibiotic therapy for a disease or condition specified in this column in relation to Chlortetracycline Capsules |
Thenalidine Tartrate Syrup ............ | Any disease or condition in a child under the age of twelve years |
Thioridazine Hydrochloride ............ | Any disease or condition in a pensioner |
| Any disease or condition in a patient receiving treatment in or at an approved hospital |
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine or Thioridazine Hydrochloride |
Thyrotropin ...................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Tragacanth B.P., Powder ............. | Ileostomy or colostomy conditions |
Fifth Schedule—continued.
Pharmaceutical Benefit. | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act. |
Triamcinolone ..................... | With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection |
Triamterene ...................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Triaziquone ...................... | |
Triethylene Thiosphosphoramide ........ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Tretamine ....................... | Malignant lymphoma and related conditions |
Trifluoperazine .................... | Any disease or condition in a pensioner |
| Any disease or condition in a patient receiving treatment in or at an approved hospital |
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine or Thioridazine Hydrochloride |
Trimeprazine Tartrate ................ | Any disease or condition in a child under the age of twelve years |
Trimetaphan Camphorsulphonate ........ | Hypotensive for anaesthesia |
Triprolidine Hydrochloride, Elixir ........ | Any disease or condition in a child under the age of twelve years |
Vadrine ........................ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Vancomycin Hydrochloride ........... | |
Velactin ......................... | With the written authority of the Director-General, galactosaemia |
Veriloid ......................... | Hypertensive crisis |
Viomycin Sulphate ................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Viomycin Sulphate and Viomycin Pantothenate Combination | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Vitamin A Activity with Aneurine Hydrochloride B.P., Riboflavine B.P., Nicotinamide B.P., Ascorbic Acid B.P. and Vitamin D | Any disease or condition in a pensioner |
Vitamin A Oral Tablets ............... | Any disease or condition in a pensioner |
Concentrated Vitamin A Solution B.P. | Any disease or condition in a child under the age of twelve years or in a pensioner |
Concentrated Vitamin A and D Solution B.P. | |
Concentrated Vitamin D Solution B.P. | Tetany |
| Any disease or condition in a child under the age of twelve years or in a pensioner |
By Authority: A. J. Arthur, Commonwealth Government Printer, Canberra.